Future Fertility Inc. has announced the closing of a US$4.1 million Series A financing round.

The round was led by M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, Germany) and Whitecap Venture Partners, with participation from new investors Sandpiper Ventures, Gaingels, and Jolt VC.

The financing will accelerate Future Fertility’s commercial expansion into Asia-Pacific and support its entry into the United States, including planned FDA 510(k) clearance for additional products as part of a broader U.S. market entry strategy.

Proceeds will also advance the development of a broader AI platform, from egg assessment through to embryo transfer, designed to support clinicians, embryologists, and patients across the full IVF journey.

M Ventures and Whitecap have supported Future Fertility’s mission to translate AI innovation into meaningful clinical outcomes since the company’s earliest stages.

Oliver Hardick, investment director, M Ventures, said: “Future Fertility is addressing a critical unmet need in reproductive medicine with a differentiated AI platform grounded in clinical data and real-world workflow integration.

“We are excited to continue supporting the company and team because we believe its technology has the potential to improve decision-making for clinicians, bring greater clarity to patients, and help advance a more personalised standard of care in fertility treatment.”

Future Fertility’s AI platform addresses a long-standing gap in fertility care: historically, there has been no objective, clinically validated method for assessing egg quality (Gardner et al., 2025), despite it being one of the most important drivers of reproductive success.

The company’s suite of deep learning tools includes VIOLET™, MAGENTA™, and ROSE™, purpose-built for egg freezing, IVF, and egg donation respectively.

The tools are based on AI models trained and validated on more than 650,000 oocyte images and are deployed in over 300 clinics across 35 countries.

Rhiannon Davies, founding and managing partner, Sandpiper Ventures, said:  “The best outcomes in fertility care globally come from better data and smarter tools. Future Fertility understands that, and they’ve built a platform that delivers on it.

“Sandpiper is proud to back a team turning rigorous science into real results for patients and clinicians alike.”

Partnerships with the world’s leading fertility networks – including IVI RMA and Eugin Group across Latin America and Europe, FertGroup Medicina Reproductiva in Brazil, and most recently announced Kato Ladies Clinic in Japan –  reflect growing demand for objective, AI-powered oocyte assessment in fertility care. In the United States, ROSE™ is newly available under an FDA 513(g) determination.

Research shows that approximately 50 per cent of IVF patients do not understand their likelihood of success, and many discontinue treatment prematurely, even though cumulative success rates improve significantly with multiple cycles (McMahon et al., 2024).

By delivering earlier clarity on egg quality, Future Fertility’s tools support more informed conversations between clinicians and patients, helping set realistic expectations and guide decisions about next steps.

Future Fertility’s growing evidence base spans seven peer-reviewed publications in Human Reproduction, Reproductive BioMedicine Online, Fertility & Sterility, and Nature’s Scientific Reports, and more than 70 scientific abstracts accepted and presented with partner clinics at conferences worldwide.

Christine Prada, CEO, Future Fertility, said: “Fertility treatment is one of the most emotionally and physically demanding experiences a person can go through.

“Every patient deserves objective data, not just a best guess, to support better decisions at critical moments in their care.

“This funding means we can bring that clarity to more patients, in more countries, at a moment when it matters most.”

Find out more about Future Fertility at futurefertility.com

By Women’s Health Week

With four weeks to go until Women’s Health Week USA, the excitement is ramping up!

The final early bird pricing closes this Friday, the full speaker lineup is confirmed, and a record number of pitch applications signals the depth of innovation now moving through the sector as we enter the Era of Scale.

Women’s Health Week USA takes place May 13-14 at the New York Academy of Medicine in New York City, bringing together 600+ senior decision makers spanning investors, founders, multinationals, payers, providers and policymakers around one shared agenda: taking women’s health from growth to scale.

Early bird tickets are available until midnight on Friday, April 17.

Book by then to save up to $600 on your place

The Full Speaker Lineup is Confirmed

The full speaker lineup has finally been confirmed, with 80+ voices spanning investment, innovation, policy, medtech and pharma.

The programme reflects the event’s 2026 theme, The Era of Scale, moving beyond early validation into the harder work of institutionalising women’s health as a category.

Confirmed speakers include Kate Ryder (Maven Clinic), Mallika Mundkur (FDA), Melanie Newman (Planned Parenthood), Nichole Young-Lin (Google), Jill Angelo (OURA), David Stern (Kindbody) and Tammy Sun (Carrot Fertility), alongside representation from the NYSE, ARPA-H, the World Health Organization, Samsung Next, Novo Holdings and more.

View the full speaker lineup

170 Pitch Applications and Counting

The Women’s Health Week USA Innovation Showcase received a record 170 applications ahead of its April 10 close, the highest number in the event’s history.

The volume reflects the growing depth of innovation in the sector, but it was the quality of submissions that stood out, with companies across Medical Devices & Therapeutics and Consumer & Tech bringing genuinely differentiated solutions to conditions that have been underserved for decades.

The selected companies will get the chance to pitch on the mainstage at the New York Academy of Medicine in front of the full audience of 600+ investors, corporates, innovators and strategic partners.

Results will be announced next week.

Register your interest to find out who makes the WHW USA Innovator Class of 2026

NYSE Partnership: A Quick Recap

For those who missed our announcement on Femtech World last week, the New York Stock Exchange is the Official Exchange Partner of Women’s Health Week USA 2026.

On the morning of May 13, WHW will feature in the NYSE Market Update, reaching approximately 200 million viewers.

Women’s Health Week will also light up the North Star Billboard in Times Square for a full week around the event, with live and taped interviews distributed across NYSE Live and Taking Stock.

It remains one of the most significant institutional endorsements the women’s health sector has seen.

Early Bird Pricing Closes This Friday

Tickets increase by up to $600 after midnight on Friday, April 17. For anyone with May 13-14 in their calendar, this week is the window to move.

Download the full programme

Register before Friday

Flora Fertility has raised US$5m in seed funding to roll out fertility insurance across the US, with plans to expand into Canada.

The round was led by ManchesterStory, with participation from Slauson & Co., TruStage Ventures, BDC Capital, Marathon Fund, Adara Venture Capital and strategic angel investors. Existing investors include Highline Beta, Everywhere Ventures and Cartography Capital.

Laura McDonald, co-founder of Flora Fertility, said: “Fertility is one of the largest uninsured financial risks people face, yet the system today only offers support once you’re already in crisis and often only if your employer provides it.

“We’re creating a new category where fertility becomes something you can proactively plan for, not just pay for when it’s too late.”

Flora says it is introducing a new InsurTech category with individually owned, portable fertility insurance designed to address a gap in healthcare cover.

The company says it wants to shift fertility from a reactive expense to a proactive, data-driven financial planning tool, using AI, personalised underwriting and risk modelling.

The platform lets people buy coverage without relying on an employer, helping it continue through job changes and different stages of life.

Flora’s policies cover a full range of fertility treatments, including diagnostics, medications, intrauterine insemination and in vitro fertilisation, with entry-level pricing starting at about US$20 a month.

The company estimates that infertility affects one in six people globally, while treatment costs can range from US$30,000 to US$50,000, leaving the vast majority of patients without access to care.

Flora says its platform currently reaches more than 10 million prospective policyholders across North America.

The funding will be used to expand Flora’s underwriting capabilities, scale distribution and further develop its platform as it seeks to establish a new market within women’s health and insurance.

Nicole Gunderson, partner at ManchesterStory, said: “Flora is building something that has never existed before, affordable, portable fertility insurance that meets the next generation of women exactly where they are.

“The InsurTech opportunity here is enormous, and the Flora team has the expertise, technology, and vision to define this category.”

Dr Christy Lane, co-founder of Flora Fertility, added: “Fertility has always been treated as unpredictable and uninsurable, but the data tells a different story.

“The earlier someone can access that coverage, the better their outcomes and the lower their costs, which is what makes this model so powerful.

“We’re turning fertility from a reactive medical expense into a proactive, data-driven financial decision.”